Risk Stratification and Treatment in Smoldering Multiple Myeloma.
MetadataShow full item record
Lussier, T., Schoebe, N., & Mai, S. (2021). Risk Stratification and Treatment in Smoldering Multiple Myeloma.. Cells, 11 (1) https://doi.org/10.3390/cells11010130
Smoldering multiple myeloma is a heterogeneous asymptomatic precursor to multiple myeloma. Since its identification in 1980, risk stratification models have been developed using two main stratification methods: clinical measurement-based and genetics-based. Clinical measurement models can be subdivided in three types: baseline measurements (performed at diagnosis), evolving measurements (performed over time during follow-up appointments), and imaging (for example, magnetic resonance imaging). Genetic approaches include gene expression profiling, DNA/RNA sequencing, and cytogenetics. It is important to accurately distinguish patients with indolent disease from those with aggressive disease, as clinical trials have shown that patients designated as "high-risk of progression" have improved outcomes when treated early. The risk stratification models, and clinical trials are discussed in this review.
smoldering multiple myeloma, risk stratification, treatment
External DOI: https://doi.org/10.3390/cells11010130
This record's URL: https://www.repository.cam.ac.uk/handle/1810/332480